RFP
NVCR icon

Root Financial Partners’s NovoCure NVCR Stock Holding History

Root Financial Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$665 Hold
61
– – ﹤0.01% 2764
2025
Q4 		$789 Buy
+61
New +$783 ﹤0.01% 2144

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Root Financial Partners's NVCR Position: Q1 2026 in Review

Root Financial Partners held its NovoCure (NVCR) position steady in Q1 2026 at 61 shares worth $665. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Root Financial Partners first reported a position in NVCR in Q4 2025 and has held it in 2 quarters since. The position peaked at $789 in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Root Financial Partners held 61 shares of NovoCure worth $665 as of Q1 2026.
  • Root Financial Partners left its NovoCure share count unchanged in Q1 2026.
  • NovoCure made up ﹤0.01% of Root Financial Partners's portfolio in Q1 2026, its #2764 holding.
  • Root Financial Partners first reported a position in NovoCure in Q4 2025 and has held it in 2 quarters since.
  • Root Financial Partners's NovoCure position peaked at $789 in Q4 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.